Fezolinetant Patent Expiration
Fezolinetant is Used for managing moderate to severe vasomotor symptoms associated with menopause. It was first introduced by Astellas Pharma Us Inc
Fezolinetant Patents
Given below is the list of patents protecting Fezolinetant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Veozah | US10836768 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Mar 28, 2034 | Astellas |
| Veozah | US9422299 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Mar 28, 2034 | Astellas |
| Veozah | US9987274 | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | Mar 28, 2034 | Astellas |
| Veozah | US8871761 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | Apr 04, 2031 | Astellas |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Fezolinetant's patents.
Latest Legal Activities on Fezolinetant's Patents
Given below is the list recent legal activities going on the following patents of Fezolinetant.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Withdrawal of Application for PTE | 05 Feb, 2026 | US10836768 |
| Withdrawal of Application for PTE | 05 Feb, 2026 | US9987274 |
| Election in Response to Notice of Final Determination | 26 Jan, 2026 | US9422299 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Dec, 2025 | US9987274 |
| Notice of Final Determination -Election Required | 24 Oct, 2025 | US9987274 |
| Notice of Final Determination -Election Required | 24 Oct, 2025 | US10836768 |
| Notice of Final Determination -Election Required | 24 Oct, 2025 | US9422299 |
| FDA Final Eligibility Letter | 18 Sep, 2025 | US9422299 |
| FDA Final Eligibility Letter | 18 Sep, 2025 | US10836768 |
| FDA Final Eligibility Letter | 18 Sep, 2025 | US9987274 |
Fezolinetant's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Fezolinetant:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
